These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15869448)

  • 1. Correlation between development of pulmonary edema and response of pulmonary metastases of metastatic melanoma and kidney cancer to high-dose continuous-infusion interleukin-2.
    Quan WD; Khan N; Ramirez M; Taylor WC; Quan F; Vinogradov M; Walker P
    Cancer Biother Radiopharm; 2005 Apr; 20(2):151-4. PubMed ID: 15869448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
    Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
    Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over.
    Quan W; Ramirez M; Taylor C; Quan F; Vinogradov M; Walker P
    Cancer Biother Radiopharm; 2005 Feb; 20(1):11-5. PubMed ID: 15778574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
    Quan WD; Quan FM; King LA; Walker PR
    Cancer Biother Radiopharm; 2008 Feb; 23(1):108-13. PubMed ID: 18298334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer.
    Quan W; Ramirez M; Taylor C; Vinogradov M; Quan F; Khan N
    Cancer Biother Radiopharm; 2005 Feb; 20(1):36-40. PubMed ID: 15778577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma].
    Nakano E
    Hinyokika Kiyo; 1992 Nov; 38(11):1305-9. PubMed ID: 1485586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
    Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
    Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous infusion interleukin-2 and intravenous famotidine in metastatic melanoma.
    Quan WD; Milligan KS; Quan FM; Cuenca RE; Khan N; Liles DK; Walker PR
    Cancer Biother Radiopharm; 2006 Dec; 21(6):607-12. PubMed ID: 17257076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
    Rosenberg SA; Lotze MT; Muul LM; Leitman S; Chang AE; Ettinghausen SE; Matory YL; Skibber JM; Shiloni E; Vetto JT
    N Engl J Med; 1985 Dec; 313(23):1485-92. PubMed ID: 3903508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
    Thompson JA; Shulman KL; Benyunes MC; Lindgren CG; Collins C; Lange PH; Bush WH; Benz LA; Fefer A
    J Clin Oncol; 1992 Jun; 10(6):960-8. PubMed ID: 1588376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer.
    Quan WD; Vinogradov M; Quan FM; Khan N; Liles DK; Walker PR
    Cancer Biother Radiopharm; 2006 Oct; 21(5):515-9. PubMed ID: 17105423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bolus high dose interleukin-2 for the treatment of malignant melanoma.
    Pappo I; Lotem M; Klein M; Orda R
    Isr Med Assoc J; 2001 Mar; 3(3):169-73. PubMed ID: 11303372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bolus followed by continuous infusion interleukin-2 in patients with metastatic malignant melanoma and kidney cancer previously treated with interleukin-2.
    Quan WD; Quan FM
    Cancer Biother Radiopharm; 2003 Aug; 18(4):535-8. PubMed ID: 14503947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.
    Bar MH; Sznol M; Atkins MB; Ciobanu N; Micetich KC; Boldt DH; Margolin KA; Aronson FR; Rayner AA; Hawkins MJ
    J Clin Oncol; 1990 Jul; 8(7):1138-47. PubMed ID: 2358835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma.
    Quan WD; Quan FM
    Cancer Biother Radiopharm; 2009 Feb; 24(1):1-6. PubMed ID: 19243244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.
    Quan W; Ramirez M; Taylor WC; Vinogradov M; Khan N; Jackson S
    Cancer Biother Radiopharm; 2004 Dec; 19(6):770-5. PubMed ID: 15665626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer.
    Quan WD; Gagnon GA; Walker PR; Quan FM
    Cancer Biother Radiopharm; 2011 Feb; 26(1):65-7. PubMed ID: 21348776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity].
    Hayakawa M
    Hinyokika Kiyo; 1992 Nov; 38(11):1311-8. PubMed ID: 1485587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chest roentgenographic abnormalities in IL-2 recipients. Incidence and correlation with clinical parameters.
    Vogelzang PJ; Bloom SM; Mier JW; Atkins MB
    Chest; 1992 Mar; 101(3):746-52. PubMed ID: 1541142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.